Trial Profile
A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Sep 2019 Planned End Date changed from 30 Jul 2021 to 31 Dec 2022.
- 13 Sep 2019 Planned primary completion date changed from 30 Jul 2020 to 31 Dec 2021.
- 19 Apr 2018 Status changed from recruiting to active, no longer recruiting.